Ac immune to regain global rights to crenezumab and semorinemab

Ac immune to regain global rights to crenezumab and semorinemab company's strategy is focused on advancing the phase 2 development of its three active immunotherapies active immunotherapy now considered to be the optimal approach for precision prevention of neurodegenerative diseases lausanne, switzerland, january 22, 2024 – ac immune sa (nasdaq: aciu), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that the company will regain all global rights to the anti-amyloid beta antibody crenezumab and the anti-tau antibody semorinemab following termination of the collaboration agreements with genentech, a member of the roche group, and roche. both antibodies have been evaluated in clinical studies for alzheimer's disease (ad).
ACIU Ratings Summary
ACIU Quant Ranking